A bupropion smoking cessation clinical trial for cancer patients

Department of Psychiatry, University of Pennsylvania, 3535 Market Street, 4th Floor, Philadelphia, PA, 19104, USA.
Cancer Causes and Control (Impact Factor: 2.74). 06/2010; 21(6):811-20. DOI: 10.1007/s10552-010-9507-8
Source: PubMed


Many cancer patients continue to smoke post diagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation.
This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7-day point-prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.
There was no main effect of bupropion vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38-4.81, p = .64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02-0.80, p = .03). Bupropion increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, bupropion reduced withdrawal symptoms and improved quality of life vs. placebo.
For patients with depression symptoms, bupropion increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with bupropion or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.

Download full-text


Available from: Corey Langer, Jun 20, 2015
1 Follower
25 Reads
  • Source
    • "Smoking cessation is also part of the treatment in the following conditions: lung cancer [21], breast reconstruction using the free TRAM flap [22], liver transplant [23] [24], colorectal surgery [25], and bone marrow transplant [26]. Evidence-based treatments of smoking habit in oncological patients include nicotine replacement therapies, bupropion , varenicline, and behavioural counselling provided individually, in groups, or by telephone [27] [28] [29]. However, clinical practice in Italian cancer departments is still far from such a standard. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Smoking cessation is necessary to reach a higher quality of life, and, for a cancer patient, it represents an important step in improving the outcome of both prognosis and therapy. Being a cancer patient addicted to nicotine may be a critical situation. We conducted a survey to monitor how many comprehensive cancer centres in Italy have an outpatient smoker clinic and which kinds of resources are available. We also inquired about inpatient services offering psychological and pharmacological support for smoking cessation, reduction, or care of acute nicotine withdrawal symptoms. What we have witnessed is a significant gap between guidelines and services. Oncologists and cancer nurses are overscheduled, with insufficient time to engage in discussion on a problem that they do not consider directly related to cancer treatment. Furthermore, smoking habits and limited training in tobacco dependence and treatment act as an important barrier and lead to the undervaluation of smokers' needs.
    Journal of Oncology 07/2011; 2011:145617. DOI:10.1155/2011/145617
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interferon-gamma (IFN-γ), a cytokine primarily secreted by T and natural killer cells regulates cell-mediated and innate immunity. Iron deficiency, a public health problem in children impairs immune function. To determine whether reduced IFN-γ contributes to impaired immunity, we measured IFN-γ in supernatants of activated (2.5 μg/ml concanavalin A, 50 ng/ml anti-CD3 antibody) spleen cells from control (C), iron-deficient (ID), pair-fed (PF), and iron-replete mice for 3 (R3) and 14 days (R14) (11-12/group). Except for iron content, the low iron (5 ppm) and control (50 ppm) diets had identical composition. Mean indices of iron status after 51 days of feeding were as follows: C=PF≈R14>R3>ID (p<0.01). Iron deficiency, but not pairfeeding reduced IFN-γ concentration in mitogen-treated cells by 30-43% (p<0.05); iron repletion improved it. Reduced IFN-γ was not simply due to differences in IL-12 (IFN-γ inducer), percentage of CD3+ T cells, or impaired cell proliferation because these indices were not always decreased. It was likely due to a defect in T cell activation that leads to IFN-γ gene expression. IFN-γ positively correlated with indicators of iron status, body, and thymus weights (r=0.238-0.472; p<0.05). Reduced IFN-γ secretion during iron deficiency may affect response to infections.
    Cytokine 12/2010; 52(3):230-7. DOI:10.1016/j.cyto.2010.08.004 · 2.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The convergence of motivated and talented clinicians, enhanced technology, treatment guidelines, models of care, and evolving hospital accreditation standards may accelerate progress in treating tobacco dependence at NCI cancer centers. With a constituency of close to 12 million Americans living with cancer,6 cancer centers have the opportunity to be the exemplars in tobacco dependence research and treatment. Cancer centers, with their talented and committed faculty, are optimally positioned to perform cutting-edge research, inform the field of tobacco dependence treatment, and meet the call to action from the NCI40 and ASCO.27 The Treating Tobacco Dependence at Cancer Centers meeting served as a springboard to develop or refine center approaches to treating tobacco dependence and expanded and energized the community of scientists devoted to this endeavor. Priorities to enhance the quality of care for tobacco dependence at cancer centers include (1) developing consensus regarding the assessment of smoking status, (2) refining electronic medical records and clinical trials to ensure the identification and referral of smokers, (3) evaluating novel treatments for cancer patients, and (4) evaluating methods to overcome barriers to providing smoking cessation treatment. The academic resources at cancer centers and the motivation and commitment of cancer center representatives suggest that the future will see cancer centers leading the way in treating tobacco dependence and contributing substantially to further reductions in tobacco-related morbidity and mortality.
    Journal of Oncology Practice 05/2011; 7(3):178-182. DOI:10.1200/JOP.2010.000175
Show more